CN Patent

CN112587672A — 用于治疗肿瘤的抗-pd-l1结合物

Assigned to Birdie Biopharmaceuticals Inc Cayman Islands · Expires 2021-04-02 · 5y expired

What this patent protects

本发明涉及用于靶向免疫疗法的抗‑PD‑L/PD‑1轴抗体结合物，以及含有所述结合物的组合物。本发明还涉及本发明的多种化合物在治疗肿瘤/癌症方面的应用。

USPTO Abstract

本发明涉及用于靶向免疫疗法的抗‑PD‑L/PD‑1轴抗体结合物，以及含有所述结合物的组合物。本发明还涉及本发明的多种化合物在治疗肿瘤/癌症方面的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN112587672A
Jurisdiction
CN
Classification
—
Expires
2021-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Birdie Biopharmaceuticals Inc Cayman Islands
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.